Oncology
Jeff Settleman, Ph.D.
Chief Scientific Officer
Dr. Jeff Settleman is the Chief Scientific Officer for Oncology Research and Development and serves as the La Jolla site head. Dr. Settleman leads all oncology research from the beginning stages of discovery to proof of concept clinical studies.
Dr. Settleman is an internationally recognized leader in molecularly targeted cancer therapeutics, the epigenetics of cancer drug resistance, and personalized cancer medicine.
Dr. Settleman held numerous notable positions in both academic research and drug discovery before joining the Pfizer team. Prior to his current role, Dr. Settleman served as Distinguished Principal Investigator and Head of Oncology Research at Calico Life Sciences. Prior to Calico, Dr. Settleman led Discovery Oncology at Genentech.
Dr. Settleman served as a Professor at the Harvard School of Medicine for 18 years and during his tenure he was named the Laurel Schwartz Professor of Oncology. During that same timeframe, Dr. Settleman served as Director of the Center for Molecular Therapeutics and Scientific Director of the Massachusetts General Hospital Cancer Center and led the Cancer Cell Biology program of the Dana-Farber/Harvard Cancer Center.
Dr. Settleman’s impressive career began at the Whitehead Institute for Biomedical Research at MIT where he was a postdoctoral fellow in Oncology and Cancer Biology.
Dr. Settleman received his Ph.D. in Genetics from Yale University and his B.A. in Neuroscience from the University of Pennsylvania. He is the author of over 240 peer-reviewed publications, many of which have appeared in Cell, Science, and Nature.
Oncology
Jeff Settleman, Ph.D.
Chief Scientific Officer
Dr. Jeff Settleman is the Chief Scientific Officer for Oncology Research and Development and serves as the La Jolla site head. Dr. Settleman leads all oncology research from the beginning stages of discovery to proof of concept clinical studies.
Dr. Settleman is an internationally recognized leader in molecularly targeted cancer therapeutics, the epigenetics of cancer drug resistance, and personalized cancer medicine.
Dr. Settleman held numerous notable positions in both academic research and drug discovery before joining the Pfizer team. Prior to his current role, Dr. Settleman served as Distinguished Principal Investigator and Head of Oncology Research at Calico Life Sciences. Prior to Calico, Dr. Settleman led Discovery Oncology at Genentech.
Dr. Settleman served as a Professor at the Harvard School of Medicine for 18 years and during his tenure he was named the Laurel Schwartz Professor of Oncology. During that same timeframe, Dr. Settleman served as Director of the Center for Molecular Therapeutics and Scientific Director of the Massachusetts General Hospital Cancer Center and led the Cancer Cell Biology program of the Dana-Farber/Harvard Cancer Center.
Dr. Settleman’s impressive career began at the Whitehead Institute for Biomedical Research at MIT where he was a postdoctoral fellow in Oncology and Cancer Biology.
Dr. Settleman received his Ph.D. in Genetics from Yale University and his B.A. in Neuroscience from the University of Pennsylvania. He is the author of over 240 peer-reviewed publications, many of which have appeared in Cell, Science, and Nature.